




# COVID-19 Clinical Update

Jonathan Vilasier Iralu, MD, FACP

Indian Health Service Chief Clinical Consultant  
for Infectious Diseases



# Disclosures



# Testing update

- ❖ Preferred reference lab test is the naso-pharyngeal swab PCR assay
- ❖ *Cepheid Xpert nucleic acid amplification assay in use at IHS sites*
- ❖ *Abbott ID NOW COVID-19 device in use IHS sites*
- ❖ qSARS-CoV-2 IgG/IgM Rapid Test (Cellex): FDA EUA
  - ❖ Lateral flow immunoassay strip with bands for IgG and IgM: 10-20 minute turn around



# Testing Update

## FDA Letter to Health Care Providers: 4/18/2020

- ❖ Use Serological tests as appropriate and be aware of their limitations
- ❖ Do not use serological tests as the sole basis to diagnosis COVID-19 but instead as information about whether a person may have been exposed
- ❖ Not all Marked serological tests have been evaluated by the FDA
- ❖ EUA out for only 4 tests:
  - ❖ Cellex
  - ❖ Vitros
  - ❖ Mt Sinai
  - ❖ DPP COVID-19



## Clinical Presentation Update

# Neurologic manifestations

- ❖ Guillain-Barre Syndrome Associated with SARS-CoV-2: Toscano et al, NEJM, 4/17/2020
  - ❖ 3 Hospitals in Northern Italy caring for 1000-1200 patients
  - ❖ 5 Patients developed Guillain-Barre Syndrome with COVID-19 infection in 5-10 days
    - ❖ 4 patients had lower-limb weakness and paresthesia
    - ❖ 1 Patient had facial diplegia, ataxia and paresthesia
    - ❖ 3 required mechanical ventilation
    - ❖ **Lumbar puncture**: all 5 had <5 cells per cubic mm, 2 had normal protein, **PCRs all negative**
    - ❖ EMG/NCV: 3 axonal, 2 demyelinating picture
    - ❖ All received IVIG → 4 severely impaired, **only 1 was able to walk** and be discharged home



# Clinical Presentation

## Pregnancy and COVID

### ❖ Clinical Characteristic of Pregnant Women with COVID-1

Chen et al, NEJM, April 2017

- ❖ 118 pregnant women Dx'd with COVID-19 identified in Wuhan, China
- ❖ Median age 31 years
- ❖ Symptoms: Fever (75%), Cough (73%)
- ❖ Lymphopenia: 44%; Abnormal CT: 79%
- ❖ 92% had mild disease, 8% had severe disease
- ❖ No maternal deaths
- ❖ 3 spontaneous & 4 induced abortions, 2 ectopic pregnancies
- ❖ 68 deliveries → Median APGAR score 9 with no neonatal asphyxia or deaths.



# Clinical Presentation

## Cardiac Manifestations

- ❖ **ST-Segment Elevation in Patients with COVID-19** Bangalore et al, NEJM, April 17
- ❖ 6 NYC Hospitals cared for 18 patients with ST-Elevation on EKG
  - ❖ Median age 63
  - ❖ 83% male
  - ❖ 33% had chest pain at time of ST-elevation
  - ❖ 44% had MI
  - ❖ 50% underwent catheterization → 67% had obstructive disease
  - ❖ **All the patients had elevated D-dimer levels**

# Hydroxychloroquine not looking so good....

## ❖ Outcome of HCQ US veterans hospitalized with COVID: Maganoli et al, MedRxiv,2020

❖ 368 Veterans with COVID-19

❖ Death Rates

- ❖ HCQ: 27.8% (AHR 2.61)
- ❖ HCQ/Azithro: 22.1% (AHR 1.14)
- ❖ No HC: 11.4%

❖ No evidence HCQ +/- Azithromycin reduced risk of mechanical ventilation

❖ HCQ alone increased mortality





# UW COVID-19 IDEA treatment guidance

COVID-19 Treatment

covid.idea.medicine.uw.edu

U.S. Clinical Trials COVID-19 Treatments Treatment Guidance Teaching Resources Master Bibliography COVID-19 Resources

University of Washington / IDEA Program

## COVID-19 Treatment

Our main goal is to provide up-to-date information and teaching slide decks focused on clinical trials and published data related to potential high-impact treatments of persons with COVID-19.

### U.S. Clinical Trials

Quick links to COVID-19 clinical trials and expanded access programs in the United States. The treatment regimens and trial list are organized alphabetically.

### Treatments

Selected high-impact and high interest COVID-19 treatments. Includes medication summaries, studies, and treatment-specific references.

### Teaching Resources

COVID-19 treatment PowerPoint slide decks. All slide decks can be downloaded and used for educational purposes without obtaining permission from our website.

#### About this website

This website was developed at the University of Washington and is produced by the University of Washington Infectious Diseases Education and Assessment (IDEA) Program.

#### Editors

**David H. Spach, MD**  
Professor of Medicine  
Division of Infectious Diseases  
University of Washington

**Gretchen Snoeyenbos Newman, MD**  
Senior Fellow  
Division of Infectious Diseases  
University of Washington

[View all Contributors](#)

SARS-CoV-2 visualization provided courtesy Cognition Studio. © 2020, Cognition Studio, Inc. All rights reserved.

Created at UNIVERSITY of WASHINGTON


Part of IDEA

remdesivir\_master.pptx

Show all

1:02 PM 4/21/2020

# NIH Treatment Guidelines



Coronavirus Disease 2019 (COVID-19) x

covid19treatmentguidelines.nih.gov

Apps Outlook Web App Book of Common... New York Times COVID resources Essential Training o...

**COVID-19 is an emerging, rapidly evolving situation.**  
Get the latest public health information from CDC: <https://www.coronavirus.gov>  
Get the latest research information from NIH: <https://www.nih.gov/coronavirus>

**NIH** COVID-19 Treatment Guidelines

## Coronavirus Disease 2019 (COVID-19) Treatment Guidelines

[VIEW GUIDELINES](#)

Credit NIAID-RML

[NIH.gov](#) | [Privacy](#) | [Accessibility](#) | [FOIA](#) | [Contact Us](#)

Site Updated: April 21, 2020

12:54 PM  
4/22/2020



# More COVID-19 Training

- ❖ **CDC:** <https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html>
- ❖ **ACP Physician Handbook:** <https://www.acponline.org/clinical-information/clinical-resources-products/coronavirus-disease-2019-covid-19-information-for-internists>
- ❖ **UW Protocols:** <https://covid-19.uwmedicine.org/Pages/default.aspx>
- **UW IDEA Program:** <https://covid.idea.medicine.uw.edu/>
- **NIH Guidelines:** <https://covid19treatmentguidelines.nih.gov/>
- ❖ **Brigham and Women's Hospital:** [covidprotocols.org](https://covidprotocols.org)



